Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NM134
- Development stage
- Preclinical
- Lead developer
- Nanomerics
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic, Topical
01
Overview
NM134 is an investigational ophthalmic drug candidate from Nanomerics for an undisclosed, potentially sight-threatening eye disease. Publicly available information indicates that it is enabled by Nanomerics' Molecular Envelope Technology, a nanomedicine delivery platform intended to enhance ocular penetration, increase drug bioavailability, and support non-irritant topical delivery across biological barriers. Nanomerics disclosed that the program received pre-IND guidance from the US FDA in 2020, but the specific active pharmaceutical ingredient, molecular target, exact indication, and clinical-stage details have not been publicly disclosed.
Beyond the preview
Go deeper on NM134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NM134.